A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open label, phase I/IIa, dose-escalation study, involving a single
injection of Temferon, an investigational advanced therapy consisting of autologous
CD34+-enriched hematopoietic stem and progenitor cells exposed to transduction with a
lentiviral vector driving myeloid specific interferon-alpha2 expression, which will be
administered to up to 21 patients affected by GBM who have an unmethylated MGMT promoter.
Part A will evaluate the safety and tolerability of 3 escalating doses of Temferon and 2
different conditioning regimens in up to 15 patients, following first line treatment. In Part
B, a further 6 patients will receive a single dose of Temferon, as identiifed from Part A.